25 LLC’s West Pharmaceutical WST Stock Holding History

25 LLC’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1	Closed	-$368	–	707
2023 Q1	$368	Buy	+1	New	+$292	﹤0.01%	492

Other funds holding WST

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

APG Asset Management Amsterdam, Netherlands $31.6B AUM 19.33% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DCP

Durable Capital Partners Bethesda, Maryland $9.71B AUM 26.27% 1-Year Est. Return

25 LLC's WST Position: Q2 2023 in Review

25 LLC sold out of West Pharmaceutical (WST) in Q2 2023, closing a stake of 1 share — an estimated $368 sold.

25 LLC first reported a position in WST in Q1 2023 and held it in 1 quarter. The position peaked at $368 in Q1 2023. 734 funds tracked by Wall St. Rank hold WST as of Q2 2023.

25 LLC reported no remaining West Pharmaceutical position as of Q2 2023 after selling out during the quarter.
25 LLC sold 1 West Pharmaceutical share in Q2 2023, an estimated $368.
25 LLC first reported a position in West Pharmaceutical in Q1 2023 and held it in 1 quarter.
25 LLC's West Pharmaceutical position peaked at $368 in Q1 2023.
734 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2023.

Based on 25 LLC's 13F filing for Q2 2023, filed 19 Jul 2023.